October 14, 2009 — Infliximab treatment is linked to lower colectomy rates in patients with moderate to severe active ulcerative colitis, according to the results of a prespecified analysis from 2 ...

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

Ciclosporin and infliximab are used as rescue therapies for the treatment of severe steroid-refractory ulcerative colitis. Now, an open-label, head-to-head randomized controlled trial has demonstrated ...

Please provide your email address to receive an email when new articles are posted on . In a multicenter, open-label trial, researchers investigated the outcomes of discontinued infliximab use in ...

The FDA has approved Remicade from Janssen Biotech to treat moderately to severely active ulcerative colitis in children over age 6 who responded inadequately to conventional therapy, according to an ...

LAS VEGAS -- Biosimilar switching was not tied to flare in patients with inflammatory bowel disease (IBD), according to a retrospective cohort study. Patients who switched from infliximab (Remicade) ...

Please provide your email address to receive an email when new articles are posted on . Inflectra demonstrated “excellent clinical efficacy and safety” in patients with inflammatory bowel disease, ...

Centocor Ortho Biotech announced results from its Phase 3 study of Remicade (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC). This ...

Medically reviewed by Mary Choy, PharmD Key Takeaways Biologic medications help reduce inflammation in ulcerative colitis. If you're new to biologics, infliximab might be your first option for ...

A new study found cyclosporine was no more effective than infliximab in patients with acute, severe ulcerative colitis refractory to intravenous steroids, according to a report by Internal Medicine ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...